Akero Therapeutics Inc (AKRO) Company Profile & Statistics

Akero Therapeutics Inc
AKRO
(Nasdaq - US)
N/A
19.64
-0.07 (-0.35%)
in:usd•As of: May 03, 2024 15:59 UTC -4
Open
20.75
High
20.75
Low
19.64

About Akero Therapeutics Inc

CEO

Andrew Cheng

Headquarters

601 gateway boulevard, suite 350

south san francisco, ca 94080, united states

Auditor

Deloitte & Touche LLP

Employees

Share Holders

Website

www.akerotx.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Akero Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing transformational treatments for non-alcoholic steatohepatitis and other serious metabolic disorders. The company's product pipeline consists of AKR-001, for the treatment of non-alcoholic steatohepatitis, which are in clinical stage. Akero Therapeutics Inc. is based in San Francisco, United States.

Akero Therapeutics Inc Statistics

Valuation Measures

Market Capitalization ²	1.36B
Enterprise Value	1.15B
Enterprise Value/EBITDA (ttm)	-6.31
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	2.05
Price to Sales (ttm)	N/A
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	0.00%
Operating Margin (ttm)	N/A
Profit Margin (ttm)	0.00%
Return on Equity (ttm)	-29.59%
Return on Invested Capital (ttm)	-29.04%
Return on Assets (ttm)	-27.10%

Income Statement

Revenue (ttm)	0.00
Revenue Per Share (ttm)	0.00
Gross Profit (ttm)	0.00
EBITDA (ttm)³	-181.95M
Net Income Avi to Common (ttm)	-151.76M
Diluted EPS (ttm)	-2.85

Share Statistics

Beta (5Y Monthly)	-0.29
52-Week Change	-56.48%
S&P500 52-Week Change	26.43%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	56.30M
Dividend Yield	0.00%
Float ⁴	62.45M
% Held by Insiders	9.69%
% Held by Institutions	N/A

Balance Sheet

Total Cash (mrq)	550.01M
Total Cash Per Share (mrq)	9.77
Total Debt (mrq)	25.02M
Total Debt/Equity (mrq)	4.67%
Current Ratio (mrq)	29.27%
Quick Ratio (mrq)	29.27%
Book Value Per Share (mrq)	9.60

Cash Flow

Operating Cash Flow Per Share (ytd)	-2.77
Free Cash Flow (ytd)	-145.37M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Akero Therapeutics Inc

Trade With A Regulated Broker